Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study

This observational study is tracking patients with primary liver cancer — either hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma — who receive minimally invasive treatments that deliver drugs or radiation directly through the liver's blood vessels. The study is not testing a new treatment; it is recording real-world data to improve future care. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with HCC or intrahepatic cholangiocarcinoma - You have received or are planned to receive one of these procedures: TAE, TACE, TARE, or DEB-TACE (all types of catheter-based liver treatments) **You may NOT be eligible if...** - You have cancer that has spread outside the liver - You have liver failure - You have abnormal blood vessel connections (shunts) in your gut that cannot be safely blocked Talk to your doctor to see if this trial is right for you.